FIELD: medicine; pharmaceuticals.
SUBSTANCE: present invention relates to novel compounds of substituted N-(3-fluoropropyl)pyrrolidine of formula (I-A), where R1 and R2 represent independently a hydrogen atom or a deuterium atom, A is an oxygen or nitrogen atom and SERM-F is a fragment of a selective estrogen receptor modulator comprising an aryl or heteroaryl group, associated with group "A" located nearby, as defined in patent claim.
EFFECT: compounds of formula (I-A) can be used as estrogen receptor inhibitors and degraders.
19 cl, 4 tbl, 258 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION CONTAINING PALBOCICLIB AND 6-(2,4-DICHLOROPHENYL)-5-[4-[(3S)-1-(3-FLUOROPROPYL)PYRROLIDINE-3-YL]-8,9-DIHYDRO-7H-BENZO[7]ANNULENE-2-CARBOXYLIC ACID AND APPLICATION THEREOF FOR TREATING CANCER | 2018 |
|
RU2764116C2 |
| CYCLIC IMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | 2018 |
|
RU2801302C2 |
| BICYCLIC COMPOUND AND USE THEREOF | 2020 |
|
RU2831535C1 |
| COMPOUNDS AND COMPOSITIONS USED FOR TREATMENT OF NTRK-RELATED DISORDERS | 2016 |
|
RU2744974C2 |
| CONDENSED TRICYCLIC BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2689777C1 |
| HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USE THEREOF | 2016 |
|
RU2743360C2 |
| BIARYL DERIVATIVES AS INHIBITORS OF PROTEIN-PROTEIN INTERACTION YAP/TAZ-TEAD | 2021 |
|
RU2830596C1 |
| RMT5 INHIBITORS | 2019 |
|
RU2814198C2 |
| GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | 2014 |
|
RU2664533C2 |
| PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | 2013 |
|
RU2658006C2 |
